How to buy Oncolytics Biotech stock (ONCY)

Oncolytics Biotech is a biotechnology business based in the US. Oncolytics Biotech shares (ONCY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.19 – a decrease of 2.46% over the previous week.

Our top picks for where to buy Oncolytics Biotech stock

Buy Oncolytics Biotech stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Oncolytics Biotech stock price (NASDAQ: ONCY)

Use our graph to track the performance of ONCY stocks over time.

Oncolytics Biotech shares at a glance

• Key figures

Information last updated 2024-10-24.

Latest market close	$1.19
52-week range	$0.84 - $1.80
50-day moving average more info button	$1.04
200-day moving average more info button	$1.07
Wall St. target price	$4.81
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.28

Is it a good time to buy Oncolytics Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oncolytics Biotech price performance over time

Historical closes compared with the close of $1.22 from 2024-10-28

1 week (2024-10-23)	1.22
1 month (2024-09-30)	40.07%
3 months (2024-07-30)	16.19%
6 months (2024-04-30)	9.91%

1 year (2023-10-30)	-21.79%
2 years (2022-10-28)	-2.40%
3 years (2021-10-29)	2.04
5 years (2019-10-30)	5.17%

Oncolytics Biotech financials

Gross profit TTM	$0
Return on assets TTM	-71.33%
Return on equity TTM	-138.22%
Profit margin	0%
Book value	$0.24
Market Capitalization more info button	$96.1 million

TTM: trailing 12 months

Oncolytics Biotech share dividends

We're not expecting Oncolytics Biotech to pay a dividend over the next 12 months.

Have Oncolytics Biotech's shares ever split?

Oncolytics Biotech's shares were split on a 10:95 basis on 24 May 2018 . So if you had owned 95 shares the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Oncolytics Biotech shares – just the quantity. However, indirectly, the new 850% higher share price could have impacted the market appetite for Oncolytics Biotech shares which in turn could have impacted Oncolytics Biotech's share price.

Oncolytics Biotech share price volatility

Over the last 12 months, Oncolytics Biotech's shares have ranged in value from as little as $0.8401 up to $1.8. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncolytics Biotech's is 1.348. This would suggest that Oncolytics Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oncolytics Biotech overview

Oncolytics Biotech Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. .

Frequently asked questions

What percentage of Oncolytics Biotech is owned by insiders or institutions?
Currently 3.817% of Oncolytics Biotech shares are held by insiders and 1.721% by institutions. When does the fiscal year end for Oncolytics Biotech?
Oncolytics Biotech's fiscal year ends in December. Where is Oncolytics Biotech based?
Oncolytics Biotech's address is: 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5 What is Oncolytics Biotech's ISIN number?
Oncolytics Biotech's international securities identification number is: CA6823108759 What is Oncolytics Biotech's CUSIP number?
Oncolytics Biotech's Committee on Uniform Securities Identification Procedures number is: 682310875